Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis
Authors:
- Dinesh KhannaDKDinesh Khanna
- Ron D HaysRHRon D Hays
- Scleroderma Collagen Type 1 Study GroupSGScleroderma Collagen Type 1 Study Group
- 3 April 2007
- journal article
- clinical trial
- Published by Springer Nature in Quality of Life Research
- Vol. 16 (6) , 1083-1092
Abstract
ObjectivesTo evaluate the reliability and validity and estimate the minimally important difference (MID) for the SF-6D in patients with systemic sclerosis (SSc). Subjects We used data from two clinical studies to analyze the SF-6D in patients with SSc: Study 1 was a cross-sectional observational study (N = 107) designed to assess three direct preference measures—the rating scale, time trade-off, and standard gamble (SG) in patients with diffuse SSc and limited SSc, and Study 2 was a 12-month randomized, placebo-controlled, clinical trial (N = 168) assessing oral bovine collagen versus placebo in diffuse SSc. Methods We assessed the test–retest reliability of the SF-6D in Study 2 over a mean (SD) 4.8 (3.0)-week interval and the agreement between the SF-6D and direct preference measures in Study 1 using intraclass correlations (ICC). The MID was estimated using three different anchors—the SF-36 change in health item (patients who answered “somewhat better” formed the MID group), the Health Assessment Questionnaire-Disability Index (HAQ-DI; change of ≥0.14 and ≥0.22) and the skin score (change of ≥5.3). Results The mean (SD) SF-6D scores were 0.61 (0.12) in Study 1 and 0.64 (0.13) in Study 2. Test–retest reliability for the SF-6D was high (ICC = 0.82 [95% CI: 0.76, 0.87]). Agreement between the SF-6D and three direct preferences measures was poor to moderate (0.16–0.52). The MID estimate for the SF-6D using the change in SF-36 item −0.012 and this level of change was similar to the no change group. The mean MID estimate for the SF-6D improvement using the HAQ-DI and skin score as anchors was 0.035 (effect size of 0.27). Conclusion This is the first study to assess the SF-6D in SSc. The SF-6D is reliable and valid in patients with SSc. We provide MID estimates that can aid in calculating sample size for clinical trials involving patients with diffuse SSc.Keywords
This publication has 42 references indexed in Scilit:
- Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine studyAnnals of the Rheumatic Diseases, 2006
- Systemic sclerosis: hypothesis-driven treatment strategiesThe Lancet, 2006
- Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung studyArthritis & Rheumatism, 2005
- Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials GroupEuropean Journal of Cancer, 2005
- A comparison of the EQ‐5D and SF‐6D across seven patient groupsHealth Economics, 2004
- Methods to Explain the Clinical Significance of Health Status MeasuresMayo Clinic Proceedings, 2002
- The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialArthritis & Rheumatism, 2001
- A power primer.Psychological Bulletin, 1992
- Measurement of health statusControlled Clinical Trials, 1989
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980